Lexo
Gait and Locomotion
LEXO® Product Film
The end-effector system allows active training and encourages the patient’s self-activity. The innovative transfer options maximize net therapy time and increase the utilization rate. With its high adaptability, LEXO® can be adjusted precisely and used for a wide range of patients. Its compact design and low height make LEXO® also easy to integrate with any therapy room.
In robotic gait rehabilitation, patients and therapists often face the same challenges.
Loss of precious time to due tedious set-up procedures, limitations in the adaptability to the patient, and unnatural walking patterns.
LEXO® is the long-desired game-changer – the end-effector system allows free joint movement, encourages the patient’s self-activity, and increases the utilization rate. The innovative transfer options maximize net therapy time, providing what is needed most: direct therapist-patient interaction.
Why LEXO®?
- Strong evidence for end-effector gait training
- Easy and fast setup as a paradigm shift in currently available robotic gait rehabilitation
- Demands patients’ self-activity
- The compact design and low height make it perfect for any therapy room
LEXO® therapy
- Innovative transfer modes
- Different body weight support modes
- PELVIS PLUS guidance
- Passive-active walking mode
- Seamlessly and electrically adjustable settings
- Task-oriented training
- Augmented Performance Feedback
- Virtual Environment
LEXO® in practice
- Active Training mode
- Demanding self-activity
- Training of physiological walking pattern
- Highly engaging for the patient
- Specific gait training (initial contact, stance phase, swing phase)
- High adaptability
- Lateral and vertical guidance with the PELVIS PLUS system
- Innovative body weight support modes
- A wide range of patients
Efficient use of therapy time
- Easy and fast setup
- Increase net therapy time
- Decrease costs
- Only 1 therapist needed a high utilization rate
Latest results
“In comparison to conventional gait rehabilitation, gait training assisted
by end-effector apparatus leads to a statistically significant and clinically relevant improvement in gait velocity and maximum walking distance after stroke.”
1 MEHRHOLZ, 2018